28547-28-6

Basic information

• Product Name: 2-Bromo-4-hydroxybenzoicacid
• Synonyms: 2-Bromo-4-hydroxybenzoicacid
• CAS NO: 28547-28-6
• Molecular Formula: C₇H₅BrO₃
• Molecular Weight: 217.0168
• Mol File: 28547-28-6.mol

Chemical Properties

• Melting Point: 151 °C
• Boiling Point: 366.3±32.0 °C(Predicted)
• Appearance: /
• Density: 1.861±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 3.22±0.10(Predicted)
• CAS DataBase Reference: 2-Bromo-4-hydroxybenzoicacid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-4-hydroxybenzoicacid(28547-28-6)
• EPA Substance Registry System: 2-Bromo-4-hydroxybenzoicacid(28547-28-6)

Safety Data

• Hazardous Substances Data: 28547-28-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-4-hydroxybenzoic acid is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique structure allows it to be a key component in the development of new medications, contributing to the advancement of pharmaceutical research and drug discovery.
Used in Dye and Pigment Industry:
In the dye and pigment industry, 2-Bromo-4-hydroxybenzoic acid serves as an intermediate in the production of dyes and pigments. Its chemical properties make it suitable for creating a wide range of colorants used in various applications, including textiles, plastics, and printing inks.
Used in Organic Synthesis:
2-Bromo-4-hydroxybenzoic acid is also utilized as a building block in the synthesis of organic compounds. Its versatile structure enables chemists to create a variety of organic molecules for different purposes, such as in the development of new materials, catalysts, and other specialty chemicals.

Upstream product

• 74317-85-4 2-bromo-4-methoxybenzoic acid 
• 2486-52-4 2-bromo-4-aminobenzoic acid 
• 22532-60-1 2-bromo-4-hydroxybenzaldehyde 
• 1208075-63-1 2-bromo-4-methoxybenzoic acid ethyl ester 
• 89691-67-8 1-(2-bromo-4-methoxyphenyl)ethanone 
• 2398-37-0 3-methoxyphenyl bromide 

Downstream Products

• 74317-85-4 2-bromo-4-methoxybenzoic acid 
• 174023-48-4 isourolithin A 
• 402925-14-8 benzyl 3-nitro-4-methoxycarbonylbenzoate 
• 73908-43-7 2-acetylamino-acrylic acid benzyl ester 
• 29921-51-5 1-iodo-7-hydroxynaphthalene 
• 402925-34-2 2-{tert-butoxyoxalyl-[4-(3-oxo-butyl)-naphthalen-1-yl]-amino}-benzoic acid benzhydryl ester 
• 402925-00-2 2-{[4-(2-acetylamino-2-allyloxycarbonyl-ethyl)-2-ethyl-phenyl]-tert-butoxyoxalyl-amino}-benzoic acid benzhydryl ester 
• 402925-12-6 2-(tert-butoxyoxalyl-{4-[2-methoxycarbonylamino-2-(2-trimethylsilanyl-ethoxycarbonyl)-ethyl]-naphthalen-1-yl}-amino)-benzoic acid benzhydryl ester 
• 436864-41-4 benzyl (2E)-2-(acetylamino)-3-(4-amino-3-ethylphenyl)-2-propenoate 
• 402925-11-5 2-(tert-butoxyoxalyl-{4-[2-methoxycarbonylamino-2-(2-trimethylsilanyl-ethoxycarbonyl)-ethyl]-naphthalen-1-yl}-amino)-benzoic acid 
• 402925-17-1 2-(7-hydroxy-naphthalen-1-ylamino)-terephthalic Acid 4-benzyl Ester 1-methyl Ester 
• 101085-03-4 2-bromo-4-hydroxybenzoic acid methyl ester 
• 1446086-68-5 benzyl 2-(3-carbamoylphenyl)-4-hydroxybenzoate 
• 1446086-69-6 cyclohexylcarbamic acid 6-benzyloxycarbonyl-3′-carbamoylbiphenyl-3-yl ester 

Relevant articles and documents

Imidazole-containing condensed tricyclic compound and application thereof

The invention discloses an imidazole-containing condensed tricyclic compound adopting the structure as shown in the formula (I) or pharmaceutically acceptable salts, stereisomers or prodrug molecules thereof. The imidazole-containing condensed tricyclic compound has the IDO1 activity regulation function, can enhance T-cell activation through blocking immune checkpoints IDO1, is used for treating IDO1-mediated immunosuppression, and therefore, can become an effective medicine for treating malignant tumors. When used together with checkpoint protein anti-body drugs or other anti-cancer drugs, the imidazole-containing condensed tricyclic compound can enhance the anti-cancer effect. Meanwhile, the imidazole-containing condensed tricyclic compound has the potential of effectively treating IDO1 abnormity related immunosuppressive diseases and has a high application value.

Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors

The peripherally restricted fatty acid amide hydrolase (FAAH) inhibitor URB937 (3, cyclohexylcarbamic acid 3′-carbamoyl-6-hydroxybiphenyl-3-yl ester) is extruded from the brain and spinal cord by the Abcg2 efflux transporter. Despite its inability to enter the central nervous system (CNS), 3 exerts profound antinociceptive effects in mice and rats, which result from the inhibition of FAAH in peripheral tissues and the consequent enhancement of anandamide signaling at CB1 cannabinoid receptors localized on sensory nerve endings. In the present study, we examined the structure-activity relationships (SAR) for the biphenyl region of compound 3, focusing on the carbamoyl and hydroxyl groups in the distal and proximal phenyl rings. Our SAR studies generated a new series of peripherally restricted FAAH inhibitors and identified compound 35 (cyclohexylcarbamic acid 3′-carbamoyl-5- hydroxybiphenyl-3-yl ester) as the most potent brain-impermeant FAAH inhibitor disclosed to date.

The direct conversion of light into continuous mechanical energy by photoreversible self-assembly: A prototype of a light-powered engine

En route to a clean engine: The concentration of a chemical system containing an azobenzene derivative can be varied cyclically by light, and this variation has been exploited to produce continuous work. The cyclic concentration change of the system is th